(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/076369 A1

(51) International Patent Classification:
A61K 31/33 (2006.01) *A61K 31/395* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/US2022/047865

(22) International Filing Date:
26 October 2022 (26.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/272,052 26 October 2021 (26.10.2021) US
63/300,145 17 January 2022 (17.01.2022) US

(71) Applicant: **SPERO THERAPEUTICS, INC.** [US/US]; 675 Massachusetts Ave., 14th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **TALLEY, Angela**; c/o Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (US). **MELNICK, David**; c/o Spero Therapeutics, Inc., 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139 (US).

(74) Agent: **MAXWELL, Leslie-Anne**; CANTOR COLBURN LLP, 20 Church St, 22nd Floor, Hartford, Connecticut 06103 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

WO 2023/076369 A1

(54) Title: HUMAN EFFICACIOUS DOSE AND DOSAGE SCHEDULE OF SPR720




Fig. 2B

(57) Abstract: The present disclose provides methods of treating NTM-PD and other bacterial infections, including pulmonary tuberculous and nontuberculous mycobacteria infections. Clinical studies have established the safety of SPR720 up to daily oral dosages of 2000 mg and shown that once daily oral dosing is sufficient to provide efficacious plasma levels of the active agent, SPR719. Clinical studies have also shown that there is no significant food effect for SPR720 and that the drug may be given in to a patient in the fed or fasted state. Clinical studies have also established that SPR720 can be administered safely to elderly patients. The present disclosure provides a method of treating a bacterial infection in a patient comprising administering a daily oral dose of SPR720, or a pharmaceutically acceptable salt thereof, the oral dose comprising 100 mg SPR720 to 1500 mg SPR720.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*